EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Human papillomavirus‐driven head and neck cancers in Japan during 2008–2009 and 2018–2019: The BROADEN study

Ken-Ichi Nibu, Nobuhiko Oridate, Yuki Saito, Montserrat Roset, Marta Forés Maresma, Daniel Cuadras, Edith Morais, Craig Roberts, Ya-Ting Chen, Jacque Spitzer, Kayo Sato, Itori Saito und 9 weitere

Cancer Science · 2024

DOI: 10.1111/cas.16230 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Ken-Ichi Nibu und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Kobe University, Graduate School of Medicine, Kobe, Hyogo, Japan. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Human Papillomavirus Viruses, Papillomavirus Infections. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is limited understanding of epidemiology and time trends of human papilloma virus (HPV)‐driven head and neck cancers (HNC) in Japan, especially outside of the oropharynx. To assess HPV‐driven HNC, a non‐interventional study (BROADEN) of HNC patients diagnosed in 2008–2009 and 2018–2019 was conducted in Japan. Adult patients with oropharyngeal, nasopharyngeal, laryngeal, hypopharyngeal or oral cavity cancers were included in this study. HPV was centrally tested using p16INK4a immunohistochemistry, HPV‐DNA PCR and HPV E6*I mRNA. HPV attributability required positivity in at least two tests (p16INK4a immunohistochemistry, HPV‐DNA PCR, HPV E6*I mRNA) in the oropharynx, and HPV‐DNA and HPV E6*I mRNA positivity for non‐oropharynx sites. Nineteen hospitals included a total of 1108 patients, of whom 981 had valid samples. Men accounted for 82% of HNC diagnoses. Patients in the earlier cohort were younger and included a higher percentage of smokers. There was an increasing trend of HPV‐driven oropharyngeal cancer over the last decade, from 44.2% to 51.7%. HPV attribution in nasopharyngeal cancers was 3.2% in 2008–2009 and 7.5% in 2018–2019; and 4.4% and 0% for larynx respectively. In total, 95.2% of HPV‐driven HNC were attributed to HPV genotypes included in the 9‐valent HPV vaccine being HPV16 the most prominent genotype. These results suggest that an epidemiologic shift is happening in Japan, with a decrease in smoking and alcohol use and an increase in HPV‐driven HNC. The increasing trend of HPV‐driven HNC in Japan highlights the need for preventive strategies to mitigate the rise of HPV‐driven HNC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Head and Neck NeoplasmsHuman Papillomavirus VirusesPapillomavirus InfectionsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedCyclin-Dependent Kinase Inhibitor p16DNA, ViralJapan

Stichwörter der Autor:innen

HPV attributabilityHPV genotypeHPV‐driven HNCHPV‐driven vaccineoropharyngeal cancer

Substanzen

Cyclin-Dependent Kinase Inhibitor p16DNA, Viral

Autor:innen und Institutionen

  • Department of Otolaryngology-Head and Neck Surgery, Kobe University, Graduate School of Medicine, Kobe, Hyogo, Japan.
  • Department of Otolaryngology, Head and Neck Surgery, School of Medicine, Yokohama City University, Yokohama, Kanagawa, Japan.
  • Department of Otolaryngology, Head and Neck Surgery, University of Tokyo, Tokyo, Japan.
  • IQVIA, Barcelona, Spain.
  • MSD France, Puteaux, France.
  • Merck & Co., Inc., Rahway, New Jersey, USA.

ORCID-Profile: Tim Waterboer

Förderung

  • Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Zitieren

APA

Nibu, K. I., Oridate, N., Saito, Y., Roset, M., Forés Maresma, M., Cuadras, D., Morais, E., Roberts, C., Chen, Y. T., Spitzer, J., Sato, K., Saito, I., Tazaki, I., Clavero, O., Schroeder, L., Alemany, L., Mehanna, H., Mirghani, H., Giuliano, A. R., …, & Waterboer, T. (2024). Human papillomavirus‐driven head and neck cancers in Japan during 2008–2009 and 2018–2019: The BROADEN study. Cancer Science. https://doi.org/10.1111/cas.16230

Vancouver

Nibu KI, Oridate N, Saito Y, Roset M, Forés Maresma M, Cuadras D, et al. Human papillomavirus‐driven head and neck cancers in Japan during 2008–2009 and 2018–2019: The BROADEN study. Cancer Science. 2024. doi:10.1111/cas.16230

BibTeX
@article{Nibu2024,
  author = {Nibu, Ken-Ichi and Oridate, Nobuhiko and Saito, Yuki and Roset, Montserrat and Forés Maresma, Marta and Cuadras, Daniel and Morais, Edith and Roberts, Craig and Chen, Ya-Ting and Spitzer, Jacque and Sato, Kayo and Saito, Itori and Tazaki, Ichiro and Clavero, Omar and Schroeder, Lea and Alemany, Laia and Mehanna, Hisham and Mirghani, Haitham and Giuliano, Anna R and Pavón, Miquel Angel and Waterboer, Tim},
  title = {Human papillomavirus‐driven head and neck cancers in Japan during 2008–2009 and 2018–2019: The BROADEN study},
  journal = {Cancer Science},
  year = {2024},
  doi = {10.1111/cas.16230}
}
Kostenlos starten →